ARS Pharmaceuticals (SPRY) Stock Forecast & Price Target

$13.03

-0.27 (-2.03%)

(As of 02:38 PM ET)

ARS Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy
Based on 6 Analyst Ratings

Based on 6 Wall Street analysts who have issued ratings for ARS Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Buy." Out of the 6 analysts, 4 have given a buy rating, and 2 have given a strong buy rating for SPRY.

Consensus Price Target

$22.75
74.60% Upside

High Forecast	$30.00
Average Forecast	$22.75
Low Forecast	$19.00

According to the 6 analysts' twelve-month price targets for ARS Pharmaceuticals, the average price target is $22.75. The highest price target for SPRY is $30.00, while the lowest price target for SPRY is $19.00. The average price target represents a forecasted upside of 74.60% from the current price of $13.03.

Type	Current Forecast 9/17/23 to 9/16/24	1 Month Ago 8/18/23 to 8/17/24	3 Months Ago 6/19/23 to 6/18/24	1 Year Ago 9/17/22 to 9/17/23
Consensus Rating	Buy	Buy	Buy	Buy
Strong Buy	2 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	4 Buy rating(s)	4 Buy rating(s)	4 Buy rating(s)	3 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$22.75	$20.33	$18.50	$15.33
Forecasted Upside	74.60% Upside	101.65% Upside	115.24% Upside	105.72% Upside

Ad DTI

Most people don’t know how important the place on this map is to trading

In a new video, I'm sitting down to show you everything about what I call "The Oklahoma Trade" including... What it is… Why it works… And while I cannot promise future returns or against losses, we will show you how anyone can start using this right away to target what could be weekly payouts in their own account.

Click here to join my free training

SPRY Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

SPRY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

ARS Pharmaceuticals Stock vs. The Competition

Type	ARS Pharmaceuticals	Medical Companies	S&P 500
Consensus Rating Score	3.33	2.77	2.50
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	71.05% Upside	3,068.57% Upside	8.62% Upside
News Sentiment Rating	Neutral News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
9/16/2024	Cantor Fitzgerald 3 of 5 stars	J. Schimmer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$30.00 ➝ $30.00	+131.66%
8/30/2024	William Blair 2 of 5 stars	L. Hanbury-Brown Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/13/2024	Raymond James 4 of 5 stars	R. Deschner Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Strong-Buy	$18.00 ➝ $22.00	+102.76%
8/12/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$19.00 ➝ $20.00	+84.16%
3/11/2024	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform	$19.00	+122.48%
3/5/2024	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	R. Ruiz Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 03:12 PM ET.

SPRY Forecast - Frequently Asked Questions

What is ARS Pharmaceuticals' forecast for 2024?: According to the research reports of 6 Wall Street equities research analysts, the average twelve-month stock price forecast for ARS Pharmaceuticals is $22.75, with a high forecast of $30.00 and a low forecast of $19.00.
Should I buy or sell ARS Pharmaceuticals stock right now?: 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ARS Pharmaceuticals in the last twelve months. There are currently 4 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SPRY shares.
Does ARS Pharmaceuticals's stock price have much upside?: According to analysts, ARS Pharmaceuticals's stock has a predicted upside of 110.65% based on their 12-month stock forecasts.
Has ARS Pharmaceuticals been upgraded by Wall Street analysts recently?: Over the previous 90 days, ARS Pharmaceuticals's stock had 2 upgrades by analysts.
What analysts cover ARS Pharmaceuticals?: ARS Pharmaceuticals has been rated by research analysts at Cantor Fitzgerald, Leerink Partners, Raymond James, and William Blair in the past 90 days.
Do Wall Street analysts like ARS Pharmaceuticals more than its competitors?: Analysts like ARS Pharmaceuticals more than other "medical" companies. The consensus rating for ARS Pharmaceuticals is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how SPRY compares to other companies.